Suboxone accounted for about 80 per cent of Indivior’s annual revenues in the US of just over $1 billion SPENCER PLATT/GETTY IMAGESAttempts by Indivior to wean itself from its reliance on opioid addiction treatments were boosted after US regulators accepted its application for a new schizophrenia drug. The Food and Drug Administration’s acceptance of the drug called RBP-7000 follows late-stage trial results and paves the way for potential marketing authorisation next July. It would alleviate the FTSE 250-listed company’s reliance on its Suboxone treatment for opioid addiction in the US where it accounted for about 80 per cent of Indivior’s annual revenues last year of just over $1 billion. Indivior, which was spun out of Reckitt Benckiser nearly three years ago, has endured a rollercoaster year. It has faced competition from generic rivals but profited from the deepening opioid addiction crisis in America, which President Trump…

Source: The Times December 13, 2017 00:03 UTC